

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

Evaluation of the protective effect of MGSO4 in Equation of the motion and lung inflammation following Amiodarone infusion in stroke

Protocol summary

Summary

Purpose: Evaluation of the protective effect of MGSO4 in Equation of the motion and lung inflammation following Amiodarone infusion in stroke. Design: This is a Randomized Controlled Clinical Trial Double Blind Prospective study that will be performed in one year interval in Sina and Baqiyatallah hospital. The patients will be assigned randomly to two groups after the consent form sign by a family member. Setting and conduct: The patients with confirmed stroke (by CT scan) will receive Amiodarone 300 mg as a bolus then 50 mg/hrs for 5 days. In the treatment group 15 cc (7.5 mg) of magnesium sulfate will be infused daily to each patient. In the control group 15 cc of placebo will be infused to each patient. Participant: The patients with confirmed stroke that consent form was signed by a family member and the patients who had atrial fibrillation and undergo treatment with amiodarone will be included in the study. Patients with Serum creatinine exceeding 2 mg/dl and presence of Hypermagnesemia will be excluded from the study. Intervention: Infusion of Magnesium sulfate to the intervention group and placebo to the control group. Main outcome measure: Measurement of MODS, APACHE II ,SOFA Score, Morbidity, Mortality ALT. AST. BUN, SCr, PH, Lactate, Total Bilirubin, Na, K, WBC, PLT, Hb IL6 IL8 SNSE S100B PAF PAI CAM 1 Elastin Fiber E-Selectin NGAL EGF TGF IgA IgG , FRC TLC MIV RV MVV , NIHSS and GCS before and after the study.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201701011165N16**

Registration date: **2017-01-29, 1395/11/10**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2017-01-29, 1395/11/10

Registrant information

Name

Yunes Panahi

Name of organization / entity

Baqiyatallah University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8821 1524

Email address

yunespanahi@bmsu.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor of research of Tehran university of medical sciences

Expected recruitment start date

2016-12-15, 1395/09/25

Expected recruitment end date

2017-12-16, 1396/09/25

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the protective effect of MGSO4 in Equation of the motion and lung inflammation following Amiodarone infusion in stroke

Public title

Evaluation of the protective effect of MGSO4 in Equation of the motion and lung inflammation following

Amiodarone infusion in stroke

Purpose

Treatment

Inclusion/Exclusion criteria

_Inclusion criteria: stroke confirmed by CT scan; Consent form was signed by family member; The patient was undergo treatment with amiodarone; The patient had Atrial fibrillation _Exclusion criteria: Serum creatinin greater than 2 mg/dl; Hypermagnasemia occur in the patient; The patient do not receive treatment for more than 24 hours.

Age

No age limit

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: **36**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Groups are randomly assigned to intervention and control group using blocks of four random design.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Baqiyatallah University of medical sciences

Street address

Mollasadra St - Sheikh bahaee

City

Tehran

Postal code

Approval date

2016-12-12, 1395/09/22

Ethics committee reference number

IR.BMSU.REC.1395.88

Health conditions studied

1

Description of health condition studied

Stroke

ICD-10 code

I64

ICD-10 code description

Stroke, not specified as haemorrhage or infarction

Primary outcomes

1

Description

Infarct size

Timepoint

Before and after of intervention

Method of measurement

CT Scan

2

Description

Immunoglobulin G, Immunoglobulin A, S100B Protein, SNSE Protein

Timepoint

Before and after of intervention

Method of measurement

Elisa Kit

Secondary outcomes

1

Description

Mortality, Vascular resistance, Delirium, Mechanical ventilation index, Multi-Organ Dysfunction Score, APACHE II Score, SOFA Score, Candida Score, Hospitalization Period

Timepoint

Before and after of intervention

Method of measurement

Questionnaire

2

Description

White blood cell count, platelet count, Hemoglobin, Alanine transaminase, Aspartate transaminase, Serum Creatinine, Serum Potassium, Serum Natrium, Serum Lactate, Total Serum Bilirubin, Blood PH

Timepoint

Before and after of intervention

Method of measurement

Blood and Serum Analysis

3

Description

Interleukin 6, Interleukin 8, Platelet-activating factor, Plasminogen activator inhibitor-1, CAM-1 Protein, Elastin Fiber Protein, E-Selectin Protein, NGAL Protein, EGF Protein, TGF Protein

Timepoint

Before and after of intervention

Method of measurement

Elisa Kit

4**Description**

Functional Residual Capacity, Respiratory Rate, Total Lung Capacity, Vital Capacity, Residual Volume, (Maximum Ventilatory Volume, Forced Expiratory Volume

Timepoint

During the study

Method of measurement

Ventilator

5**Description**

Glasgow Coma Scale, National Institutes of Health Stroke Scale

Timepoint

During the study

Method of measurement

Questionnaire

Intervention groups**1****Description**

Treatment group will receive 7.5 gr (15 cc) of magnesium sulfate SID for 5 days.

Category

Treatment - Drugs

2**Description**

control group will receive 15 cc of placebo SID for 5 days.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Sina Hospital

Full name of responsible person

Dr Yunes Panahi

Street address

Hassan abad st - imam khomeini St

City

Tehran

2**Recruitment center****Name of recruitment center**

Baqiyatallah hospital

Full name of responsible person

Dr Yunes Panahi

Street address

Mollasadra st - sheikh bahae st.

City

Tehran

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tehran University of medical sciences (Vice Chancellor of research)

Full name of responsible person

Dr. Masoud Yunesian

Street address

6th floor, Central Organization of U of T, Keshavarz Blvd.

City

Tehran

Grant name

-

Grant code / Reference number

-

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of medical sciences (Vice Chancellor of research)

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Baqiyatallah University of medical sciences

Full name of responsible person

Yunes Panahi

Position

Professor/ PharmD

Other areas of specialty/work**Street address**

Mollasadra St.

City

tehran

Postal code**Phone**

+98 21 8248 2503

Fax

Email

yunespanahi@yahoo.com

Web page address**Email**

Yunespanahi@yahoo.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

baiyatallah university of medical sciences

Full name of responsible person

Yunes Panahi

Position

Professor/ PharmD

Other areas of specialty/work**Street address**

Mollasadra St. Sheikh bahaee st.

City

Tehran

Postal code**Phone**

+98 21 8248 2503

Fax**Person responsible for updating data****Contact****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty